Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | ADA | P00813 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27803093 | 0.86 | ACHE (0.37) | KDM5AACHEKDM4CKDM5BCPB2 | |
| SCHEMBL3009277 | 0.85 | CPB2 (0.40) | KDM5ACPB2ADA | |
| SCHEMBL27781545 | 0.85 | KDM5A (0.35) | KDM5AACHETGFBR1TGFBR2KDM4C | |
| SCHEMBL27781574 | 0.78 | ADA (0.51) | KDM5AADA | |
| SCHEMBL2999032 | 0.75 | CPB2 (0.41) | CPB2 | |
| SCHEMBL2176873 | 0.73 | CYP2C9 (0.53) | CPB2 | |
| SCHEMBL29215894 | 0.72 | KDM5A (0.46) | KDM5AKDM4CKDM5BADA | |
| SCHEMBL27781647 | 0.72 | KDM5A (0.46) | KDM5AKDM4CKDM5BADA | |
| SCHEMBL29215817 | 0.72 | KDM5A (0.46) | KDM5AKDM4CKDM5BADA | |
| SCHEMBL3012492 | 0.71 | CPB2 (0.52) | KDM5AKDM5BCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| CN-101679293-A | Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases | VALETTA HEALTH B V | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | KDM5A 3919/4885ACHE 4605/4885TGFBR1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.